Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

Intuitive Surgical is Down this Year Despite Double-Digit Growth. Is Its 33x Valuation Still Justified?

Company update Earnings report AI-generated analysis

πŸ“‰ ISRG shares have declined nearly 24% since the start of 2026, underperforming the S&P 500 despite strong underlying business fundamentals.

πŸ’° The company trades at a forward P/E of approximately 36.36x, representing a substantial premium over traditional medical device peers like Medtronic.

πŸ“ˆ Q2 2026 revenue surged 19% year-over-year to $2.89 billion, driven by double-digit growth in both da Vinci and Ion procedures.

πŸ”§ The installed base of surgical systems expanded significantly, with da Vinci units rising 12% to 11,710 systems and Ion units increasing 21% to 1,096 systems.

πŸš€ Placement activity accelerated in Q2 with 468 da Vinci systems placed, including a strong push for the newer da Vinci 5 platform.

πŸ“… Management forecasts worldwide da Vinci procedure growth between 13.5% and 15.5% for the remainder of 2026.

πŸ’Έ GAAP net income increased to $818 million in Q2, though non-GAAP operating expenses are projected to rise 11-13% in 2026.

⚠️ Tariffs are expected to negatively impact gross margins by approximately one percentage point in the coming year.

πŸ—οΈ The high valuation implies that continued exceptional execution is required to justify the premium multiple over time.

Bullish Signals
  • Intuitive Surgical achieved double-digit growth in procedures, revenue, and installed base during Q2 2026, demonstrating resilient business performance.
  • Revenue increased 19% year-over-year to $2.89 billion in the second quarter of 2026, validating demand for its robotic surgery platforms.
  • The company successfully placed 468 da Vinci systems in Q2, indicating strong market penetration and adoption of newer technology like the da Vinci 5.
  • GAAP net income rose to $818 million in Q2 2026, reflecting strong profitability despite a challenging macro environment.
Risk Factors
  • The stock has underperformed the broader market with a nearly 24% decline since the start of 2026, putting its premium valuation under scrutiny.
  • Tariffs are projected to reduce gross margins by approximately one percentage point, adding a specific headwind to profitability.
  • The forward P/E of roughly 36x is significantly higher than peers like Medtronic, leaving little room for disappointment in future earnings growth.
Full Analysis
Intuitive Surgical (ISRG) faces a divergence between its robust business performance and its stock market trajectory, having declined nearly 24% in 2026 despite double-digit growth in procedures, revenue, and installed base. The company's forward P/E ratio stands at approximately 36x, reflecting a significant premium over peers like Medtronic that investors are paying for its dominant position in robotic-assisted surgery. In the second quarter of 2026, ISRG reported revenue growth of 19% to $2.89 billion, driven by a 16% increase in worldwide da Vinci and Ion procedures. The installed base expanded significantly with 11,710 da Vinci systems and 1,096 Ion systems, while the company placed 468 new da Vinci systems, including a notable uptake of the newer da Vinci 5 platform. Management expects procedure growth to continue at approximately 13.5% to 15.5% for the full year 2026. However, the high valuation leaves little room for error; while GAAP net income rose to $818 million, the company anticipates non-GAAP operating expenses will increase by 11% to 13% in 2026, and tariffs are expected to reduce gross margins by about one percentage point.